271 related articles for article (PubMed ID: 30253811)
1. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y
J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
3. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y
J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
5. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
6. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Ali FS; Qiao W; Lum P; Raju G; Shuttlesworth G; Stroehlein J; Diab A
J Immunother Cancer; 2018 May; 6(1):37. PubMed ID: 29747688
[TBL] [Abstract][Full Text] [Related]
7. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
[TBL] [Abstract][Full Text] [Related]
8. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
Choi K; Abu-Sbeih H; Samdani R; Nogueras Gonzalez G; Raju GS; Richards DM; Gao J; Subudhi S; Stroehlein J; Wang Y
Inflamm Bowel Dis; 2019 Jan; 25(2):385-393. PubMed ID: 30169584
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy.
Tang T; Abu-Sbeih H; Ma W; Lu Y; Luo W; Foo WC; Richards DM; Halperin DM; Ge PS; Wang Y
Clin Colorectal Cancer; 2020 Sep; 19(3):e117-e123. PubMed ID: 32284253
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
[TBL] [Abstract][Full Text] [Related]
12. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis.
Inoue S; Kono M; Fukuda H; Shimamoto Y; Nakagawa K; Ohmori M; Iwagami H; Matsuno K; Iwatsubo T; Nakahira H; Matsuura N; Shichijo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Kitamura M; Nakatsuka S; Kunimasa K; Kumagai T; Isei T; Ishihara R
J Gastroenterol Hepatol; 2021 May; 36(5):1180-1186. PubMed ID: 32888202
[TBL] [Abstract][Full Text] [Related]
13. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.
Tang T; Abu-Sbeih H; Luo W; Lum P; Qiao W; Bresalier RS; Richards DM; Wang Y
Scand J Gastroenterol; 2019 May; 54(5):538-545. PubMed ID: 31079556
[No Abstract] [Full Text] [Related]
14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung VTF; Gupta T; Olsson-Brown A; Subramanian S; Sasson SC; Heseltine J; Fryer E; Collantes E; Sacco JJ; Pirmohamed M; Simmons A; Klenerman P; Tuthill M; Protheroe AS; Chitnis M; Fairfax BP; Payne MJ; Middleton MR; Brain O
Br J Cancer; 2020 Jul; 123(2):207-215. PubMed ID: 32418993
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features of Rituximab-associated Gastrointestinal Toxicities.
Mallepally N; Abu-Sbeih H; Ahmed O; Chen E; Shafi MA; Neelapu SS; Wang Y
Am J Clin Oncol; 2019 Jun; 42(6):539-545. PubMed ID: 31136371
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H; Faleck DM; Ricciuti B; Mendelsohn RB; Naqash AR; Cohen JV; Sellers MC; Balaji A; Ben-Betzalel G; Hajir I; Zhang J; Awad MM; Leonardi GC; Johnson DB; Pinato DJ; Owen DH; Weiss SA; Lamberti G; Lythgoe MP; Manuzzi L; Arnold C; Qiao W; Naidoo J; Markel G; Powell N; Yeung SJ; Sharon E; Dougan M; Wang Y
J Clin Oncol; 2020 Feb; 38(6):576-583. PubMed ID: 31800340
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study.
Kou F; Li J; Cao Y; Peng Z; Xu T; Shen L; Gong J; Wang X
Front Oncol; 2023; 13():1285478. PubMed ID: 38090496
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
